|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.454 EUR | -2.57% |
|
-5.97% | -33.45% |
| 04/12 | Evotec's Partner Bayer Starts Mid-stage Study of Genetic Kidney Disease Drug | MT |
| 04/12 | Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome | CI |
Business description: Evotec SE
Number of employees: 4,788
Sales by Activity: Evotec SE
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Discovery and Preclinical Development | - | - | - | - | 61Cr |
Just - Evotec Biologics | - | - | - | - | 19Cr |
EVT Innovate | 11Cr | 15Cr | 20Cr | 27Cr | - |
EVT Execute | 49Cr | 61Cr | 74Cr | 74Cr | - |
Transition | 2.18Cr | - | - | - | - |
Intersegment Elimination | -12Cr | -14Cr | -19Cr | -22Cr | -12.08L |
Geographical breakdown of sales: Evotec SE
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
USA | 25Cr | - | - | 46Cr | 45Cr |
Switzerland | - | - | - | 6.49Cr | 11Cr |
United Kingdom | 9.4Cr | - | - | 8.64Cr | 9.25Cr |
Rest of the World | 7.77Cr | - | - | 9.52Cr | 8.23Cr |
Germany | 4.43Cr | - | - | 3.41Cr | 3.29Cr |
France | 3.71Cr | - | - | 3.2Cr | 1.99Cr |
Unallocated | - | - | - | - | 1.44Cr |
Executive Committee: Evotec SE
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01/07/2024 | |
| Director of Finance/CFO | - | 01/03/2025 | |
Cord Dohrmann
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/09/2010 |
Volker Braun
IRC | Investor Relations Contact | - | - |
Bernd Mühlenweg
PRN | Corporate Officer/Principal | 53 | - |
Composition of the Board of Directors: Evotec SE
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 15/06/2021 | |
Roland Sackers
BRD | Director/Board Member | 57 | 19/06/2019 |
| Director/Board Member | 63 | 01/06/2021 | |
| Director/Board Member | 42 | 22/06/2022 | |
Duncan McHale
BRD | Director/Board Member | 58 | 10/06/2024 |
Wesley Wheeler
BRD | Director/Board Member | 69 | 10/06/2024 |
Thomas Hanke
BRD | Director/Board Member | - | - |
Company details: Evotec SE
Group companies: Evotec SE
| Name | Category and Sector |
|---|---|
Evotec (France) SAS
 Evotec (France) SAS Engages in research and development of physical and natural sciences | |
Evotec (France) SAS
Evotec (France) SAS Engages in research and development of physical and natural sciences | |
Evotec (UK) Ltd.
 Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural sciences and engineering |
Miscellaneous Commercial Services
|
Evotec (UK) Ltd.
Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural sciences and engineering |
Miscellaneous Commercial Services
|
Evotec International GmbH
 Evotec International GmbH Miscellaneous Commercial ServicesCommercial Services Develops and provides drugs specializing in the treatment of CNS disorders |
Miscellaneous Commercial Services
|
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.57% | -5.97% | -37.81% | -65.98% | 111.93Cr | |
| -0.95% | -1.24% | +4.02% | +12.98% | 4.74TCr | |
| +0.41% | -1.81% | +11.46% | +8.74% | 3.85TCr | |
| -2.56% | -5.20% | +57.04% | +66.98% | 3.57TCr | |
| +0.38% | -1.24% | +11.14% | +21.03% | 2.72TCr | |
| +0.61% | -7.48% | +56.37% | +165.22% | 1.54TCr | |
| +1.48% | +2.42% | +65.68% | +229.77% | 1.54TCr | |
| +0.05% | +0.47% | -14.53% | -5.60% | 1.42TCr | |
| +0.43% | -1.63% | +51.98% | - | 1.36TCr | |
| -0.16% | -1.27% | +114.33% | +113.82% | 1.32TCr | |
| Average | -0.29% | -2.31% | +31.97% | +60.77% | 2.22TCr | |
| Weighted average by Cap. | -0.35% | -2.11% | +30.78% | +54.56% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EVT Stock
- Company Evotec SE
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition